The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Evert de Jonge

Department of Intensive Care

Academic Medical Center

University of Amsterdam

Netherlands

[email]@amc.uva.nl

Name/email consistency: high

 
 
 
 
 
 
 

Affiliation

  • Department of Intensive Care, Academic Medical Center, University of Amsterdam, Netherlands. 1998 - 2009

References

  1. Patients with cancer on the ICU: the times they are changing. de Jonge, E., Bos, M.M. Crit. Care (2009) [Pubmed]
  2. Association between administered oxygen, arterial partial oxygen pressure and mortality in mechanically ventilated intensive care unit patients. de Jonge, E., Peelen, L., Keijzers, P.J., Joore, H., de Lange, D., van der Voort, P.H., Bosman, R.J., de Waal, R.A., Wesselink, R., de Keizer, N.F. Crit. Care (2008) [Pubmed]
  3. Effects of selective decontamination of digestive tract on mortality and antibiotic resistance in the intensive-care unit. de Jonge, E. Curr. Opin. Crit. Care (2005) [Pubmed]
  4. Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects. de Jonge, E., Friederich, P.W., Vlasuk, G.P., Rote, W.E., Vroom, M.B., Levi, M., van der Poll, T. Clin. Diagn. Lab. Immunol. (2003) [Pubmed]
  5. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. de Jonge, E., Schultz, M.J., Spanjaard, L., Bossuyt, P.M., Vroom, M.B., Dankert, J., Kesecioglu, J. Lancet (2003) [Pubmed]
  6. Drotrecogin alfa Eli Lilly. de Jonge, E. IDrugs (2002) [Pubmed]
  7. Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. de Jonge, E., Dekkers, P.E., Creasey, A.A., Hack, C.E., Paulson, S.K., Karim, A., Kesecioglu, J., Levi, M., van Deventer, S.J., van der Poll, T. J. Infect. Dis. (2001) [Pubmed]
  8. Effects of different plasma substitutes on blood coagulation: a comparative review. de Jonge, E., Levi, M. Crit. Care Med. (2001) [Pubmed]
  9. Anticoagulant factor concentrates in disseminated intravascular coagulation: rationale for use and clinical experience. de Jonge, E., van der Poll, T., Kesecioglu, J., Levi, M. Semin. Thromb. Hemost. (2001) [Pubmed]
  10. Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects. de Jonge, E., Levi, M., Büller, H.R., Berends, F., Kesecioglu, J. Intensive. Care. Med (2001) [Pubmed]
  11. Current drug treatment strategies for disseminated intravascular coagulation. de Jonge, E., Levi, M., Stoutenbeek, C.P., van Deventer, S.J. Drugs (1998) [Pubmed]
 
WikiGenes - Universities